High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts

被引：52

作者：

Naranbhai, Vivek ^{[1
,2
,3
,4
]}

Chang, Christina C. ^{[4
,5
,6
,7
]}

Beltran, Wilfredo F. Garcia ^{[8
]}

Miller, Tyler E. ^{[8
]}

Astudillo, Michael G. ^{[8
]}

Villalba, Julian A. ^{[8
]}

Yang, Diane ^{[8
]}

Gelfand, Jeffrey ^{[3
,9
]}

Bernstein, Bradley E. ^{[8
]}

Feldman, Jared ^{[10
]}

Hauser, Blake M. ^{[10
]}

Caradonna, Timothy M. ^{[10
]}

Alter, Galit ^{[10
]}

Murali, Mandakolathur R. ^{[3
,11
]}

Jasrasaria, Rashmi ^{[3
,12
]}

Quinlan, Joan ^{[13
]}

Xerras, Dean C. ^{[3
,12
]}

Betancourt, Joseph R. ^{[13
,14
]}

Louis, David N. ^{[8
]}

Schmidt, Aaron G. ^{[10
]}

Lennerz, Jochen ^{[8
,15
]}

Poznansky, Mark C. ^{[3
,9
]}

Iafrate, A. John ^{[8
,15
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA

[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[4] Ctr Aids Programme Res South Africa, Durban, South Africa

[5] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia

[6] Monash Univ, Melbourne, Vic, Australia

[7] Univ New South Wales, Kirby Inst, Therapeut & Vaccine Res Programme, Sydney, NSW, Australia

[8] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[9] Massachusetts Gen Hosp, Vaccine & Immunotherapy Ctr, Div Infect Dis, Boston, MA 02114 USA

[10] MIT, Ragon Inst Massachusetts Gen Hosp, Cambridge, MA USA

[11] Massachusetts Gen Hosp, Dept Allergy & Immunol, Boston, MA 02114 USA

[12] Massachusetts Gen Hosp, MGH Chelsea HealthCare Ctr, Boston, MA 02114 USA

[13] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA

[14] Massachusetts Gen Hosp, Ctr Divers & Inclus, Boston, MA 02114 USA

[15] Massachusetts Gen Hosp, Ctr Integrated Diagnost, Boston, MA 02114 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2020年 / 222卷 / 12期

基金：

英国医学研究理事会; 美国国家卫生研究院;

关键词：

SARS-CoV-2; COVID-19; antibodies; serosurveillance; epidemiology; validation; lateral flow assay; immunoassay; seroprevalence; Chelsea Massachusetts;

D O I：

10.1093/infdis/jiaa579

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-ofcare lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM(+)IgG(+), 9.0% IgM(+)IgG(-), and 5.0% IgM-IgG(+)). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM(+)IgG(-). These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.

引用

页码：1955 / 1959

页数：5

共 14 条

[1]

Borremans B, 2020, QUANTIFYING ANTIBODY, V2020

[2]

Bryan A, 2020, PERFORMANCE CHARACTE, DOI [10.1101/2020.04.27.20082362, DOI 10.1101/2020.04.27.20082362, 10.1101/2020.04.27.20082362v1]

[3]

Feng X, 2020, 20098426 BIORXIV, DOI [10.1101/2020.05.13, DOI 10.1101/2020.05.13]

[4]

Larremore D.B., 2020, "Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys," can be found under, DOI 10.1101/2020.04.15.20067066

[5]

Li ZT, 2020, J MED VIROL, V92, P1518, DOI [10.1002/jmv.25727, 10.12052/gdutxb.200076]

[6]

Long QX, 2020, NAT MED, V26, P845, DOI [10.1038/s41591-020-0897-1, 10.1093/cid/ciaa344]

[7]

Massachusetts Department of Public Health, 2020, COVID 19 DASHB WEEKL

[8]

Massachusetts Department of Public Health, 2020, COR DIS 2019 COVID 1

[9]

Massachusetts Department of Public Health, 2020, COVID 19 DASHB MON

[10]

Nart J., COVID19 TREND TRACKE

← 1 2 →